Biocon

Biocon opens ₹4,500 crore QIP, sets floor price at ₹387.74 per share

Biocon has opened a ₹4,500-crore QIP and fixed a floor price of ₹387.74 per share. The company said it may offer a discount of up to 5% and will finalise pricing with lead managers

Stocks to Watch today, Jan 7: Titan, Biocon, Godrej Con, Lodha, YES Bank

Stocks to Watch today, January 7, 2026: Godrej Consumer, Titan, Jubilant FoodWorks, YES Bank are among key stocks that will be in focus today

Ajanta Pharma hits over 5-month high after partnering with Biocon

Ajanta Pharma share price rose as it has entered into an in-licensing agreement with Biocon Limited for the right to market Semaglutide

Ajanta Pharma signs pact with Biocon to sell semaglutide in 26 countries

Ajanta Pharma has signed an in-licensing pact with Biocon to market semaglutide across 26 countries in Africa, the Middle East and Central Asia, subject to approvals

Stocks to Watch today, Dec 16: Biocon, EIH, Zee Media, HCLTech, MTNL, SBI

Stocks to Watch today, December 16, 2025: HCLTech, MTNL, SBI, EIH and others will remain on investors' radar today

Biocon launches drugs for diabetes and obesity treatment in Netherlands

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for liraglutide from the Medicines and Healthcare Products Regulatory Agency

Synergy gains from stake purchase positive for pharma major Biocon

Brokerages say Biocon's move to fully acquire Biocon Biologics simplifies structure and unlocks value, but near-term stock pressure likely due to dilution and fundraising

Stocks to Watch today: Adani Enterprises, ICICI Bank, Biocon, Ola Electric

Stocks to Watch today, December 8, 2025: Bajaj Finserv, ONGC, AU Small Finance Bank, P N Gadgil Jewellers, Cochin Shipyard, Delhivery, and TVS Motor Company are among the top stock to remain in focus

Even today, I think BBL at $5.5 billion is undervalued: Kiran Mazumdar-Shaw

'Can reinvest operating cash back into biz to scale up GLP-1s'

Biocon to integrate Biocon Biologics in $5.5-bn tranx, pivots away from IPO

Proposed transaction will result in Biocon Biologics becoming a wholly-owned subsidiary of Biocon, simplifying the group structure, and strengthening the consolidated balance sheet

Biocon to make Biocon Biologics a wholly owned subsidiary in $5.5 bn deal

Biocon Biologics Chief Executive Shreehas Tambe will become CEO and managing director of the combined entity post-integration

Biocon board to weigh BBL stake buyout, fundraising options on December 6

Biocon's board will meet on December 6 to consider acquiring Biocon Biologics shares from minority investors through cash or a share swap, and to approve fundraising options such as QIP, rights issue

Biocon scales biosimilars, cuts debt; analysts bullish post Q2 results

MOFSL and JM Financial retained their Buy ratings, while Nuvama upgraded Biocon to Buy from Hold after the company posted a net profit of ₹85 crore in Q2FY26

Debt restructuring to reduce interest costs by ₹300 cr by FY27: Biocon CEO

CEO Shreehas Tambe says debt reduction, US state tie-ups, and five fresh product launches will strengthen Biocon Biologics' global biosimilar play

Biocon Q2FY26 results: Consolidated net profit at ₹84.5 cr, revenue up 21%

The biosimilars segment, operated by Biocon Biologics, reported revenues of Rs 2,721 crore, reflecting strong 25 per cent year-on-year growth

Q2 FY26 results today: Bajaj Finserv, Biocon, Godrej, and more on Nov 11

Q2FY26 company results: Firms including Bajaj Holdings & Investment, Bharat Forge, Bosch, Cera Sanitaryware and Hindustan Copper are also to release their July-September earnings reports today

Biocon arm Syngene eyes late-stage clinical supplies amid regulatory shift

As regulators ease biosimilar trial norms, Syngene International is expanding into late-stage clinical supply production, betting on biologics and peptide manufacturing for growth

USFDA's new biosimilar norms to woo more players, fast-track mkt entry

Indian cos like Biocon, DRL, Intas, Lupin stand to benefit from the proposed move

Biocon Biologics gets Health Canada approval for Yesintek, Yesintek I.V.

The approval of Yesintek and Yesintek I.V., biosimilars to Stelara, strengthens Biocon Biologics' presence in North America and expands its immunology portfolio

Biocon gets Health Canada nod for biosimilars Yesintek, Yesintek IV

Biocon Ltd on Thursday said its arm Biocon Biologics Ltd has received an approval from Health Canada for chronic autoimmune conditions treatment medications Yesintek and Yesintek IV. The notice of compliance (NOC) granted by Health Canada is for Yesintek (ustekinumab injection) and Yesintek IV (ustekinumab for injection, solution for intravenous infusion), Biocon Ltd said in a regulatory filing. Yesintek and Yesintek IV are biosimilars to Stelara (ustekinumab injection) and Stelara IV (ustekinumab for injection, solution for intravenous infusion), respectively. The approval was granted on October 17, paving the way for Canadian commercial availability in mid-October, the company said. "Health Canada's approval of Yesintek marks a significant milestone in our mission to expand global access to high-quality biosimilars," Biocon Biologics CEO & Managing Director Shreehas Tambe said. He further said, "Building on our successful US launch, this approval strengthens our presence in ...